Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.

MLA

Cragg, Louise H., et al. “Phase I Trial and Correlative Laboratory Studies of Bryostatin 1 (NSC 339555) and High-Dose 1-B-D-Arabinofuranosylcytosine in Patients with Refractory Acute Leukemia.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 8, no. 7, July 2002, pp. 2123–33. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=12114412&authtype=sso&custid=ns315887.

APA

Cragg, L. H., Andreeff, M., Feldman, E., Roberts, J., Murgo, A., Winning, M., Tombes, M. B., Roboz, G., Kramer, L., & Grant, S. (2002). Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 8(7), 2123–2133.

Chicago

Cragg, Louise H, Michael Andreeff, Eric Feldman, John Roberts, Anthony Murgo, Mary Winning, Mary Beth Tombes, Gail Roboz, Lora Kramer, and Steven Grant. 2002. “Phase I Trial and Correlative Laboratory Studies of Bryostatin 1 (NSC 339555) and High-Dose 1-B-D-Arabinofuranosylcytosine in Patients with Refractory Acute Leukemia.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 8 (7): 2123–33. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=12114412&authtype=sso&custid=ns315887.